{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:07:56Z","timestamp":1789826876945,"version":"4.0.1"},"reference-count":42,"publisher":"The Journal of Rheumatology","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:sec><jats:title>Objective.<\/jats:title><jats:p>To describe the ways in which serum urate (SU) and gout flares are reported in clinical trials, and to propose minimum reporting requirements.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods.<\/jats:title><jats:p>This analysis was done as part of a systematic review aiming to validate SU as a biomarker for gout. The ways in which SU and flares were reported were extracted from each study by 2 reviewers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>A total of 22 studies (10 randomized controlled trials, 3 open-label extension studies, and 9 observational studies) were identified. There were 3 broad categories of SU reporting: percentage at target SU, mean SU, and change in SU. A median of 2 (range 1\u20133) categories were reported across all studies. The most common method of reporting SU was percentage at target in 17\/22 (77.3%) studies, with all studies reporting a target of SU &lt; 6 mg\/dl. There were 12\/22 (54.5%) studies reporting mean SU at some time after study entry, with 7 (58.3%) of these reporting at more than just the final study visit. Two ways of reporting gout flares were identified: mean flare rate and percentage of participants with flares. There was variability in time periods over which flares rates were reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>There is inconsistent reporting of SU and flares in gout studies. Reporting the percentage of participants who achieve a target SU reflects international treatment guidelines. SU should also be reported as a continuous variable with a relevant central and dispersion estimate. Gout flares should be reported as both percentage of participants and mean flare rates at each timepoint.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.170911","type":"journal-article","created":{"date-parts":[[2017,12,15]],"date-time":"2017-12-15T20:20:44Z","timestamp":1513369244000},"page":"419-424","source":"Crossref","is-referenced-by-count":18,"title":["Variability in the Reporting of Serum Urate and Flares in Gout Clinical Trials: Need for Minimum Reporting Requirements"],"prefix":"10.3899","volume":"45","author":[{"given":"Lisa K.","family":"Stamp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie B.","family":"Morillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Dalbeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasvinder A.","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Lassere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2017,12,15]]},"reference":[{"key":"2018112909375678000_45.3.419.1","doi-asserted-by":"publisher","DOI":"10.1177\/0141076815625599"},{"key":"2018112909375678000_45.3.419.2","doi-asserted-by":"publisher","DOI":"10.1186\/ar4145"},{"key":"2018112909375678000_45.3.419.3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c869"},{"key":"2018112909375678000_45.3.419.4","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099111"},{"key":"2018112909375678000_45.3.419.5","first-page":"527","article-title":"Proceedings. Maastricht, the Netherlands, April 29\u2013May 3, 1992","volume":"20","year":"1992","journal-title":"J Rheumatol"},{"key":"2018112909375678000_45.3.419.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.079970"},{"issue":"Suppl 3","key":"2018112909375678000_45.3.419.7","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s13063-017-1978-4","article-title":"The COMET Handbook: version 1.0","volume":"18","author":"Williamson","year":"2017","journal-title":"Trials"},{"key":"2018112909375678000_45.3.419.8","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090371"},{"key":"2018112909375678000_45.3.419.9","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.144063"},{"key":"2018112909375678000_45.3.419.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-209020"},{"key":"2018112909375678000_45.3.419.11","doi-asserted-by":"publisher","DOI":"10.1002\/art.33483"},{"key":"2018112909375678000_45.3.419.12","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu424"},{"key":"2018112909375678000_45.3.419.13","doi-asserted-by":"crossref","first-page":"e012026","DOI":"10.1136\/bmjopen-2016-012026","article-title":"Using serum urate as a validated surrogate endpoint for flares in patients with gout: protocol for a systematic review and meta-regression analysis","volume":"6","author":"Morillon","year":"2016","journal-title":"BMJ Open"},{"key":"2018112909375678000_45.3.419.14","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12266"},{"key":"2018112909375678000_45.3.419.15","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/1756-185X.12648","article-title":"A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia","volume":"18","author":"Xu","year":"2015","journal-title":"Int J Rheum Dis"},{"key":"2018112909375678000_45.3.419.16","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21772"},{"key":"2018112909375678000_45.3.419.17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209707"},{"key":"2018112909375678000_45.3.419.18","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1093\/rheumatology\/kex250","article-title":"The British Society for Rheumatology Guideline for the Management of Gout","volume":"56","author":"Hui","year":"2017","journal-title":"Rheumatology"},{"key":"2018112909375678000_45.3.419.19","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203325"},{"key":"2018112909375678000_45.3.419.20","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.060368"},{"key":"2018112909375678000_45.3.419.21","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.131244"},{"key":"2018112909375678000_45.3.419.22","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/acr.22741","article-title":"Development of preliminary remission criteria for gout using Delphi and 1000Minds consensus exercises","volume":"68","author":"de Lautour","year":"2016","journal-title":"Arthritis Care Res"},{"key":"2018112909375678000_45.3.419.23","first-page":"409","article-title":"Comparative trial of azapropazone and indomethacin plus allopurinol in acute gout and hyperuricaemia","volume":"37","author":"Fraser","year":"1987","journal-title":"J Royal Coll Gen Pract"},{"key":"2018112909375678000_45.3.419.24","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1002\/art.1780341203","article-title":"Influence of antihyperuricaemic therapy on the clinical and radiographic progression of gout","volume":"34","author":"McCarthy","year":"1991","journal-title":"Arthritis Rheum"},{"key":"2018112909375678000_45.3.419.25","first-page":"577","article-title":"Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?","volume":"28","author":"Li-Yu","year":"2001","journal-title":"J Rheumatol"},{"key":"2018112909375678000_45.3.419.26","doi-asserted-by":"publisher","DOI":"10.1002\/art.10511"},{"key":"2018112909375678000_45.3.419.27","first-page":"37","article-title":"Benzbromarone therapy in management of refractory gout","volume":"118","author":"Kumar","year":"2005","journal-title":"N Z Med J"},{"key":"2018112909375678000_45.3.419.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050373"},{"key":"2018112909375678000_45.3.419.29","first-page":"2093","article-title":"Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study","volume":"34","author":"Richette","year":"2007","journal-title":"J Rheumatol"},{"key":"2018112909375678000_45.3.419.30","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.091462"},{"key":"2018112909375678000_45.3.419.31","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080814"},{"key":"2018112909375678000_45.3.419.32","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ken457"},{"key":"2018112909375678000_45.3.419.33","doi-asserted-by":"publisher","DOI":"10.1186\/ar2978"},{"key":"2018112909375678000_45.3.419.34","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1169"},{"key":"2018112909375678000_45.3.419.35","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq346"},{"key":"2018112909375678000_45.3.419.36","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201795"},{"key":"2018112909375678000_45.3.419.37","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201676"},{"key":"2018112909375678000_45.3.419.38","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/15257770.2013.853786","article-title":"Efficacy and safety of a urate lowering regimen in primary gout","volume":"33","author":"Bailen","year":"2014","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"2018112909375678000_45.3.419.39","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.semarthrit.2015.05.005","article-title":"An open-label, 6-month study of allopurinol safety in gout: The LASSO study","volume":"2015","author":"Becker","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"2018112909375678000_45.3.419.40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/03009742.2015.1099729","article-title":"Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study","volume":"45","author":"Yu","year":"2016","journal-title":"Scandinavian J Rheumatol"},{"key":"2018112909375678000_45.3.419.41","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/art.39840","article-title":"Lesinurad combined with allopurinol: randomized, double-blind, placebo-controlled study in gout subjects with inadequate response to standard of care allopurinol (a US-based study)","volume":"69","author":"Saag","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2018112909375678000_45.3.419.42","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209213"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.170911","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T14:24:53Z","timestamp":1543501493000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.170911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,15]]},"references-count":42,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2018,3,1]]},"published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.3899\/jrheum.170911"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.170911","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,15]]}}}